The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review.
Systematic review · Can Respir J · 2025. Source record refreshed; an explanation has not been reviewed.
About this paper
This page identifies the publication and its source. A checked explanation of its findings is not yet available.
Reading this record
Checking bibliographic metadata does not verify a study’s conclusions or any advice previously linked to it.
Publication details
The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review.
Al Oweidat KS, Abdulelah AA, Toubasi AA et al.
Can Respir J · 2025
- PubMed ID
- 40630797
- Record checked
A checked publication record confirms source details. It does not verify a health claim or assess the quality of the study. Our approach.
Keep your place in the research.
Save this source or mark it as read.